NEOSUMMIT-01 Trial: Perioperative Toripalimab in Locally Advanced Gastric or Gastroesophageal Junction Cancer

For decades, the gold standard for treating locally advanced gastric and gastroesophageal junction (GEJ) cancers has been a grueling combination of surgery and perioperative chemotherapy. While regimens like SOX, CapOx, and FLOT have provided a foundation, the clinical reality has remained sobering: relapse—particularly the dreaded peritoneal recurrence—continues to haunt patients and limit long-term survival.

However, a paradigm shift is underway. The latest data from the NEOSUMMIT-01 trial suggests that we are moving beyond the “chemo-only” era. By integrating PD-1 blockade into the perioperative window, clinicians are seeing a translation of early pathologic success into actual, long-term survival.

The Shift Toward Immune-Chemotherapy Strategies

The future of gastric cancer treatment is no longer just about removing the tumor; It’s about systemic sterilization. The “perioperative” approach—treating before and after surgery—is evolving into a sophisticated immune-chemotherapy strategy designed to wipe out micrometastases before the surgeon even makes an incision.

In the NEOSUMMIT-01 trial, the addition of toripalimab (an anti-PD-1 antibody) to chemotherapy showed a stark improvement in outcomes. The 3-year event-free survival (EFS) jumped to 74.7% compared to 56.2% for those receiving chemotherapy alone. This suggests that immunotherapy doesn’t just shrink the primary tumor; it trains the immune system to police the body long after the operation is over.

Breaking the Barrier of Peritoneal Recurrence

Perhaps the most groundbreaking trend highlighted by recent data is the targeted reduction of peritoneal relapse. Traditionally, peritoneal recurrence has been a “death sentence” or a catalyst for rapid decline because it is notoriously resistant to systemic therapy.

The NEOSUMMIT-01 results indicate a dramatic drop in peritoneal metastasis, falling from 36.8% down to 15.0% with the addition of toripalimab. This suggests that PD-1 inhibitors may provide a protective “shield” in the abdominal cavity, addressing a critical gap in our current therapeutic arsenal.

As we look forward, the industry is likely to focus on “peritoneal-first” immunotherapy combinations, potentially combining systemic PD-1 blockades with localized delivery methods to further eradicate these stubborn clusters of cancer cells.

Moving Beyond the MSI-H Niche

For years, immunotherapy in gastric cancer was largely reserved for a small subset of patients: those with high microsatellite instability (MSI-H) or deficient mismatch repair (dMMR). These tumors are highly “immunogenic,” meaning they are easy for the immune system to spot and attack.

The real trend, however, is the expansion of these benefits to the broader population. The success of toripalimab in the NEOSUMMIT-01 trial persisted even after excluding dMMR tumors. This opens the door for a future where pMMR (mismatch repair proficient) patients—the vast majority of gastric cancer cases—can benefit from immune-checkpoint inhibitors.

This evolution marks a transition from “niche” immunotherapy to “universal” perioperative immune-modulation, potentially redefining the standard of care for all locally advanced G/GEJ adenocarcinoma patients.

Optimizing the Chemotherapy Backbone

Immunotherapy does not work in a vacuum; it requires a partner. The synergy between toripalimab and oxaliplatin-based regimens (like SOX and CapOx) is a key takeaway from recent studies. While FLOT is common in the West, the effectiveness of SOX/CapOx in Asian treatment settings provides a blueprint for regionalized, optimized care.

Future trends will likely involve “biomarker-driven” backbone selection—where the chemotherapy regimen is chosen specifically to prime the tumor environment for the immunotherapy to work more effectively. We are moving toward a “1+1=3” effect, where the combination is exponentially more powerful than the sum of its parts.

For more detailed clinical data on these advancements, you can explore the full study via ASCO Publications or read our guide on modern gastric cancer treatment options.

Frequently Asked Questions

What is perioperative therapy?
Perioperative therapy refers to a treatment plan that includes both preoperative (neoadjuvant) and postoperative (adjuvant) therapies, usually chemotherapy or immunotherapy, designed to shrink the tumor before surgery and kill remaining cells afterward.

How does toripalimab differ from standard chemotherapy?
While chemotherapy attacks rapidly dividing cells (both cancerous and healthy), toripalimab is a PD-1 inhibitor. It “unmasks” the cancer cells, allowing the patient’s own immune system to recognize and destroy the tumor.

Why is the 3-year survival rate significant?
In gastric cancer, many patients relapse within the first two years. Achieving an overall survival rate of 81.3% at the 3-year mark indicates a durable response that suggests a higher likelihood of long-term cure.